Takeda Pharmaceutical Co Adr (TAK)

Dec 10, 2025

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Dec 10, 2025

Dec 06, 2025

Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.

Dec 06, 2025

Dec 05, 2025

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz

Dec 05, 2025

Dec 04, 2025

INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com

Dec 04, 2025

Nov 18, 2025

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 18, 2025

Nov 04, 2025

Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 04, 2025

Nov 02, 2025

ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛

Nov 02, 2025

Oct 30, 2025

Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria

Oct 30, 2025

Oct 24, 2025

CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com

Oct 24, 2025

Oct 22, 2025

BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com

Oct 22, 2025

Oct 22, 2025

CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com

Oct 22, 2025

Oct 21, 2025

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se

Oct 21, 2025

Oct 21, 2025

INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com

Oct 21, 2025

Oct 21, 2025

INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com

Oct 21, 2025

Oct 20, 2025

Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 20, 2025

Oct 14, 2025

TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN

Oct 14, 2025

Oct 13, 2025

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 13, 2025

Oct 08, 2025

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo

Oct 08, 2025

Sep 26, 2025

Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com

Sep 26, 2025

Sep 17, 2025

5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool

Sep 17, 2025

Sep 08, 2025

Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com

Sep 08, 2025

Sep 06, 2025

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se

Sep 06, 2025

Aug 25, 2025

Japan's Takeda weighs India for global trials to speed up drug launches - MSN

Aug 25, 2025

Aug 22, 2025

Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN

Aug 22, 2025

Aug 22, 2025

IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl

Aug 22, 2025

Aug 21, 2025

IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN

Aug 21, 2025

Aug 20, 2025

IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl

Aug 20, 2025

Aug 18, 2025

Waltham biotech’s latest pharma deal valued at $2B - The Business Journals

Aug 18, 2025

Aug 15, 2025

TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com

Aug 15, 2025

Aug 14, 2025

Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World

Aug 14, 2025